Skip to content
sellWeak cluster of 210b5-1 plan

Pamela J. Cramer sold $1.2M of RYTM

Chief Human Resources Officer at RHYTHM PHARMACEUTICALS, INC.. 20,760 shares at an average of $60.14, traded Apr 8, 2025, filed Apr 10, 2025.

Warning score
33
Value
$1.2M
20,760 shares
Holdings after
19,209
-52% from before
From 52-week low
+23%
low $46.95, close $57.73
From 52-week high
-14%
high $67.33, as of Apr 8, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $1.2M at market
    +25
  • Share of holdings sold
    Sold 52% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -0.8%, 3m +54.0%, 6m +73.3%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

RYTMOct 9, 2026 · close 90.78
Since filing Apr 10, 2025: +57.0%SPY +50.9% · excess +6.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-25-033821, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Apr 8, 2025MOption exercise
Common Stock10b5-1
+14,060$6.80$96k33,269Apr 10, 2025
Apr 8, 2025MOption exercise
Common Stock10b5-1
+6,700$27.35$183k39,969Apr 10, 2025
Apr 8, 2025SOpen-market sale
Common Stock10b5-1
-6,430$58.36$375k33,539Apr 10, 2025
Apr 8, 2025SOpen-market sale
Common Stock10b5-1
-600$59.00$35k32,939Apr 10, 2025
Apr 8, 2025SOpen-market sale
Common Stock10b5-1
-6,700$60.00$402k26,239Apr 10, 2025
Apr 8, 2025SOpen-market sale
Common Stock10b5-1
-7,030$62.00$436k19,209Apr 10, 2025
Apr 8, 2025MOption exercise
Stock Options (Right to Buy)derivative10b5-1
+14,060$0.00$042,190Apr 10, 2025
Apr 8, 2025MOption exercise
Stock Options (Right to Buy)derivative10b5-1
+6,700$0.00$020,100Apr 10, 2025

Related signals

Other insiders at RHYTHM PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
28Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
David P Meeker
President and CEO
$5.1M
50,000 shares
-17%
30Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Hunter C Smith
Chief Financial Officer
$6.6M
62,774 shares
-36%
37Weak
RYTMsell
RHYTHM PHARMACEUTICALS, INC.
Christopher Paul German
Corporate Controller & CAO
$428k
4,643 shares
-100%
38Weak
RYTMsell
RHYTHM PHARMACEUTICALS, INC.
Christopher Paul German
Corporate Controller & CAO
$503k
5,614 shares
-97%
24Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Hunter C Smith
Chief Financial Officer
$806k
7,954 shares
-7%
23Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Hunter C Smith
Chief Financial Officer
$709k
7,071 shares
-6%
23Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Hunter C Smith
Chief Financial Officer
$703k
6,628 shares
-5%
0Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Pamela J. Cramer
Chief Human Resources Officer
$372k
3,350 shares
-14%
0Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Pamela J. Cramer
Chief Human Resources Officer
$352k
3,350 shares
-14%
33Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Pamela J. Cramer
Chief Human Resources Officer
$2.3M
22,866 shares
-57%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.